Prostate cancer detection rate of multiparametric magnetic resonance imaging / transrectal ultrasound fusion prostate biopsy . Impact of clinical indications on biopsy outcome

OPEN ACCESS © Copyright by Società Italiana di Gerontologia e Geriatria (SIGG) ❚ Received: October 29, 2018 Accepted: December 09, 2018 ❚ Correspondence: Luigi Cormio, Urology and Renal Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, viale Luigi Pinto 251, 71122 Foggia, Italy. Tel .+39 0881 732111. Fax +39 0881 736056. E-mail: luigi.cormio@unifg.it Short CommuniCation

[1]  F. Sanguedolce,et al.  Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy , 2018, Front. Oncol..

[2]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[3]  M. Aapro,et al.  Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. , 2017, European urology.

[4]  R. Faletti,et al.  Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer. , 2017, European urology.

[5]  P Choyke,et al.  Changes in prostate cancer detection rate of MRI-TRUS fusion vs systematic biopsy over time: evidence of a learning curve , 2017, Prostate Cancer and Prostatic Diseases.

[6]  F. Sanguedolce,et al.  Typing the atypical: Diagnostic issues and predictive markers in suspicious prostate lesions , 2017, Critical reviews in clinical laboratory sciences.

[7]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[8]  G. Preminger,et al.  Antibiotic use and the prevention and management of infectious complications in stone disease , 2017, World Journal of Urology.

[9]  G. Carrieri,et al.  Presence and severity of lower urinary tract symptoms are inversely correlated with the risk of prostate cancer on prostate biopsy. , 2017, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[10]  P. Choyke,et al.  Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. , 2016, The Journal of urology.

[11]  M. Brunelli,et al.  Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review. , 2016, Clinical genitourinary cancer.

[12]  Saila Kauppila,et al.  Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. , 2016, European urology.

[13]  F. Sanguedolce,et al.  Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate Biopsy , 2016, Medicine.

[14]  C. Magi-Galluzzi,et al.  Novel biomarkers and genomic tests in prostate cancer: a critical analysis. , 2015, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[15]  G. Stallone,et al.  Post-void residual urinary volume is an independent predictor of biopsy results in men at risk for prostate cancer. , 2015, Anticancer research.

[16]  Baris Turkbey,et al.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.

[17]  J. J. de la Rosette,et al.  Impact of case volume on outcomes of ureteroscopy for ureteral stones: the clinical research office of the endourological society ureteroscopy global study. , 2014, European urology.

[18]  E. Ranieri,et al.  Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. , 2014, Cancer research.

[19]  F. Montorsi,et al.  Prostate cancer detection rates in different biopsy schemes. Which cores for which patients? , 2014, World Journal of Urology.

[20]  A. Gross,et al.  Nephrostomy in percutaneous nephrolithotomy (PCNL): does nephrostomy tube size matter? Results from The Global PCNL Study from The Clinical Research Office Endourology Society , 2013, World Journal of Urology.

[21]  C. Magi-Galluzzi,et al.  Prostate cancer patients older than 70 years treated by radical prostatectomy have higher biochemical recurrence rate than their matched younger counterpart , 2013, The Prostate.

[22]  G. Morgia,et al.  Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. , 2013, Urology.

[23]  M. Roobol,et al.  Positive predictive value of prostate biopsy indicated by prostate‐specific‐antigen‐based prostate cancer screening: trends over time in a European randomized trial * , 2012, BJU international.

[24]  Jens-Uwe Stolzenburg,et al.  Exit strategies following percutaneous nephrolithotomy (PCNL): a comparison of surgical outcomes in the Clinical Research Office of the Endourological Society (CROES) PCNL Global Study , 2012, World Journal of Urology.

[25]  F. Sanguedolce,et al.  Combined perianal‐intrarectal (PI) lidocaine‐prilocaine (LP) cream and lidocaine‐ketorolac gel provide better pain relief than combined PI LP cream and periprostatic nerve block during transrectal prostate biopsy , 2012, BJU international.

[26]  M. Kattan,et al.  Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer , 2012, BJU international.

[27]  A. Doble,et al.  Risk profiles of prostate cancers identified from UK primary care using national referral guidelines , 2012, British Journal of Cancer.

[28]  B. K. Park,et al.  Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. , 2011, AJR. American journal of roentgenology.

[29]  Benjamin D Smith,et al.  Future of cancer incidence in the United States: burdens upon an aging, changing nation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Malcolm Kohler,et al.  A prospective evaluation , 2016 .

[31]  C. Catalano,et al.  Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. , 2015, Urologic oncology.

[32]  F. Sanguedolce,et al.  Noninfiltrative anesthesia for transrectal prostate biopsy: a randomized prospective study comparing lidocaine-prilocaine cream and lidocaine-ketorolac gel. , 2013, Urologic oncology.

[33]  Michael Stöckle,et al.  [Localised prostate cancer: the PREFERE trial]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[34]  Yongmei Chen,et al.  Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. , 2011, The Journal of urology.

[35]  A. Bergen,et al.  Cigarette smoking. , 1999, Journal of the National Cancer Institute.